鸡毒支原体对大环内酯类抗生素的耐药判定标准研究现状
|
摘要
鸡的慢性呼吸道疾病是鸡常发的一种传染病,对家禽养殖业有非常大的危害,其致病菌主要是鸡毒支原体。大环内酯类抗生素是治疗鸡毒支原体病的常用药物之一,但由于不规范用药的问题,致使鸡毒支原体对大环内酯类抗生素产生了一定的耐药性,而且呈现越来越严重的趋势。为了指导临床合理用药,进而有效控制耐药性问题,制定耐药判定标准是必要条件。现综述了鸡毒支原体对大环内酯类抗生素耐药判定标准的研究现状,根据美国和欧盟耐药判定标准制定程序,为我国制定鸡毒支原体对大环内酯类抗生素的耐药判定标准奠定基础。
The chronic respiratory disease of chicken is a common infectious disease of chicken,which has a great harm to poultry breeding industry,the main pathogenic bacteria is Mycoplasma gallisepticum.Macrolide antibiotics is one of the most commonly used drugs in the treatment of Mycoplasma gallisepticum disease.However,due to the problem of non-standard drug use,the resistance to Mycoplasma gallisepticum macrolides has become more and more serious.In order to guide rational drug use in clinic,and effectively control drug resistance,it is necessary to formulate criteria for drug resistance.The Mycoplasma gallisepticumcriteria of macrolide resistance was reviewed,according to the United States and the European Union resistance criteria and procedures for resistance to macrolides in order to lay the foundation for China to develop criteria for Myco plasmagallisepticum.
The chronic respiratory disease of chicken is a common infectious disease of chicken,which has a great harm to poultry breeding industry,the main pathogenic bacteria is Mycoplasma gallisepticum.Macrolide antibiotics is one of the most commonly used drugs in the treatment of Mycoplasma gallisepticum disease.However,due to the problem of non-standard drug use,the resistance to Mycoplasma gallisepticum macrolides has become more and more serious.In order to guide rational drug use in clinic,and effectively control drug resistance,it is necessary to formulate criteria for drug resistance.The Mycoplasma gallisepticumcriteria of macrolide resistance was reviewed,according to the United States and the European Union resistance criteria and procedures for resistance to macrolides in order to lay the foundation for China to develop criteria for Myco plasmagallisepticum.
引文
[1]LEY D H,YODER H W Jr.Mycoplasma gallisepticum infection[M]//CALNEK B W,BARNES H J,BEARD C W,eds.Diseases of poultry.9th ed.Ames,IA:Iowa State University Press,1997:194-207.
[2]LEVISOHN SKLEVEN S H.Avian mycoplasmosis(Mycoplasma gallisepticum)[J].Rev Scientif Et Tech,2000,19(2):425-442.
[3]PENNYCOTT T W.Causes of mortality and culling in adult pheasants[J].Vet Rec,2000,146(10):273-278.
[4]BENCINA D,MRZEL I,ROJS O Z,et al.Characterisation of Mycoplasma gallisepticumstrains involved in respiratory disease in pheasants and peafowl[J].Vet Rec,2003,152(8):230.
[5]XIAO X,SUN J,CHEN Y,et al.Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6in Mycoplasma gallisepticumand Escherichia coli co-infected chickens[J].Vet J,2015,204(1):54-59.
[6]RAUTIAIN E N,EWALLGREN P.Aspects of the transmission of protection against Mycoplasma hyopneumoniae from sow to offspring[J].J Vet Med,2001,48(1):55-65.
[7]SWAYNE D E,GLISSON J R,MCDOUGALD L R,et al.Diseases of poultry[M].Ames,IA:Iowa State University Press,2013.
[8]BENOINA D,TADINA T,DORRER D.Natural infection of geese with Mycoplasma gallisepticum and Mycoplasma synoviae and egg transmission of the mycoplasmas[J].Avian Pathol,1988,17(2):441-449.
[9]MAROIS C,DUFOUR-GESBERT F,KEMPF I.Polymerase chain reaction for detection of Mycoplasma gallisepticumin environmental samples[J].Avian Pathol,2002,31(2):163.
[10] SASIPREEYAJAN J,HALVORSON D A,NEWMAN J A.Bacterin to control the vertical transmission of Mycoplasma gallisepticum in chickens[J].Avian Dis,1985,29(4):1256.
[11] REIMSCHUESSEL R,MILLER R A,GIESEKER C M.Antimicrobial drug use in aquaculture[M]//Antimicrobial therapy in veterinary medicine.Fifth edition.John Wiley&Sons,Inc,2013:569-587.
[12] NAN Z,YE X,WU Y,et al.Determination of the mutant selection window and evaluation of the killing of Mycoplasma gallisepticum by danofloxacin,doxycycline,tilmicosin,tylvalosin and valnemulin[J].PLoS One,2017,12(1):e0169134.
[13] SULEJMAN A,DANIELE A,ANDREA B,et al.Macrolides[J].Kirk-Othmer Encyclopedia Chem Technol,2008,53(5):374-377.
[14]林伯全,廖惠珍,杜海江,等.免疫鸡毒支原体F弱毒株对SPF鸡Bu-1a+B、TCRγδ+CD3+T细胞及血清IgM、IgG、IgA的影响[J].中国兽医学报,2015,35(4):549-552.
[15] FEIZI A,BABAKHANI S,NIKPIRAN H.Seroprevalence of Mycoplasma gallisepticuminfection in Iranian north-west broiler breeder farms[J].An Biol Res,2013,4(4):109-111.
[16] GERCHMAN I.Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry[J].Vet Res,2011,42(1):90.
[17] ZANELLA A,MARTINO P A,PRATELLI A,et al.Development of antibiotic resistance in Mycoplasma gallisepticum in vitro[J].Avian Pathol,1998,27(6):591-596.
[18] GHARAIBEH SAL-RASHDAN M.Change in antimicrobial susceptibility of Mycoplasma gallisepticumfield isolates[J].Vet Microbiol,2011,150(3/4):379.
[19] SAMUEL S O,ABODERIN A O,SALAMI T A T,et al.Campylobacter antimicrobial drug resistance among humans in Ilorin,Nigeria[J].Nigerian Med J,2009(1):56.
[20] TURNIDGE JPATERSON D L.Setting and revising antibacterial susceptibility breakpoints[J].Clin Microbiol Rev,2007,20(3):391.
[21]赵源昌.细菌对抗菌药物的敏感性试验[J].农家之友(理论版),2008(11):53-56.
[22] BROWN DMACGOWAN A.Harmonization of antimicrobial susceptibility testing breakpoints in Europe:implications for reporting intermediate susceptibility[J].J Antimicrob Chemother,2010,65(2):183-185.
[23] BYWATER R,SILLEY P,SIMJEE S.Antimicrobial breakpoints—Definitions and conflicting requirements[J].Vet Microbiol,2006,118(1/2):158.
[24] STASS HDALHOFF A.The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints[J].Infection,2005,33(2):29-35.
[25] SOUSSY C J,CLUZEL R,COURVALIN P.Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France[J].Eur J Clin Microbiol Infect Dis,1994,13(3):238-246.
[26] TURNIDGE J,KAHLMETER G,KRONVALL G.Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values[J].Clin Microbiol Infect Off Publicat Eur Soc Clin Microbiol Infect Dis,2006,12(5):418.
[27] BTTNER A,DE J A,SCHMID P,et al.Determination of breakpoints for veterinary medically relevant antibiotics for resistance assessment of veterinary pathogens[J].Berliner Und Münchener Tierrztliche Wochenschrift,2000,113(9):344-347.
[28]童明庆.抗菌药的PK/PD理论及其在新抗菌药的药效研究中应用[J].中国临床药理学杂志,2008,24(5):475-480.
[29] XU C,ZHANG J,ZHAO Z,et al.Antimicrobial susceptibility and PFGE genotyping of Haemophilus parasuis isolates from pigs in South China(2008-2010)[J].J Vet Med Sci,2011,73(8):1061.
[30]潘华芳.猪沙门菌对恩诺沙星耐药判定标准研究[D].湖北武汉:华中农业大学,2012.
[31]张朋.副猪嗜血杆菌对替米考星野生型折点和药效学折点研究[D].湖北武汉:华中农业大学,2015.
[32] JACOBS M R,MITHAL Y,ROBINSBROWNE R M,et al.Antimicrobial susceptibility testing of pneumococci:determination of Kirby-Bauer breakpoints for penicillin G,erythromycin,clindamycin,tetracycline,chloramphenicol,and rifampin[J].Antimicrob Agents Chemotherapy,1979,16(2):190-197.
[33]曾振灵,王燕,王令,等.三种抗菌药体外对鸡败血支原体的敏感性[J].中国预防兽医学报,2002(2):48-50.
[34]李宏胜,张继瑜,周绪正,等.替米考星与泰乐菌素对畜禽常见病原菌抑菌作用比较[J].动物医学进展,2006,27(2):94-96.
[35]刘轶秋,张媛,薛青红,等.恩诺沙星与其他抗菌药对鸡毒支原体的体外联合抑菌试验[J].中国兽药杂志,2013(12):46-50.
[36]王建国.鸡毒支原体大环内酯类耐药性诱导及其核蛋白突变分析[D].北京:中国农业大学,2006.
[37]陈凤梅,牛钟相,程光民,等.替米考星用于鸡毒支原体和大肠杆菌混合感染的临床试验[J].中国家禽,2004(21):17-19.
[38]王志强,卜仕金,郑月华,等.替米考星(tilmicosin)对鸡败血霉形体感染的药效学[J].中国兽医学报,2004,24(4):386-388.
[39]颜友荣,方向红.替米考星对鸡败血支原体的体外抑菌试验[J].畜牧兽医杂志,2007(3):8-10.
[40]钟妮娜,王红宁,廖德惠,等.抗菌药物联合应用对鸡毒支原体的药敏试验[J].中国兽医杂志,1998(8):7-8.
[41]孔意端,林居纯,陈继荣,等.鸡毒支原体不同地区分离株对常用抗菌药物的敏感性试验[J].动物医学进展,2008(6):35-38.
[42]郭伟娜.鸡毒霉形体不同菌株的药敏实验及耐药机制的研究[D].湖北武汉:华中农业大学,2007.
[43]李东.湖北地区鸡毒霉形体的分离鉴定及分子流行病学研究[D].湖北武汉:华中农业大学,2011.
[44]林居纯,曾振灵,吴聪明,等.鸡毒支原体的耐药性调查[J].中国兽医杂志,2008(8):40-41.
[45]隋兆峰,张侃吉,徐建义,等.山东地区鸡毒支原体分离鉴定及耐药性监测[J].中国家禽,2016(14):51-54.
[46]徐建义.山东地区肉鸡鸡败血支原体感染流行病学调查及综合防治措施的非军事化[D].江苏南京:南京农业大学,2005.
[47] JORDAN F T W,FORRESTER C A,RIPLEY P H,et al.In vitro and in vivo comparisons of valnemulin,tiamulin,tylosin,enrofloxacin,and lincomycin/spectinomycin against Mycoplasma gallisepticum[J].Avian Dis,1998,42(4):738-745.
[48] AMMAR A M,ABD ELAZIZ N K,GHARIB A A,et al.Mutations of domainⅤin 23Sribosomal RNA of macrolide-resistant Mycoplasma gallisepticum isolates in Egypt[J].J Infect Deve Countries,2016,10(8):807.
[49] JOHN T L P D.Setting and revising antibacterial susceptibility break points[J].Clin Microbiol Rev,2007,20(3):1245.
[50]王强,霍伟,任元刚,等.鸡霉形体的分离与药敏试验[J].山东畜牧兽医,2016(9):11-12.
[51] KATZ LASHLEY G W.Translation and protein synthesis:macrolides[J].Chem Rev,2005,105(2):499-528.
[52] JENNI SBAN N.The chemistry of protein synthesis and voyage through the ribosomal tunnel[J].Curr Opin Struct Biol,2003,13(2):212-219.
[53] KANOH SRUBIN B K.Mechanisms of action and clinical application of macrolides as immunomodulatory medications[J].Clin Microbiol Rev,2010,23(3):590.
[54]李玉保,王守荣,刘玉庆,等.肉鸡气管阻塞呼吸系统细菌多样性分析[J].中国兽医学报,2016,36(7):1123-1130.
[55]VESTER BDOUTHWAITE S.Macrolide resistance conferred by base substitutions in 23SrRNA[J].Antimicrob Agent Chemotherapy,2001,45(1):1.
[56] DUMKE R,TH RMER A,JACOBS E.Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden,Germany[J].Diagn Microbiol Infect Dis,2016,86(2):221.
[57] ROBERTS M C,SUTCLIFFE J,COURVALIN P,et al.Nomenclature for macrolide and macrolide-lincosamidestreptogramin B resistance determinants[J].Antimicrob Agent Chemotherapy,1999,43(12):2823.
[58] FELMINGHAM D,ROBBINS M J,SANGHRAJKA M,et al.The in vitro activity of some 14-,15-and 16-membered macrolides against Staphylococcus spp.,Legionella spp.,Mycoplasma spp.and Ureaplasma urealyticum[J].Drug Under Exp Clin Res,1991,17(2):91-99.
[59] LI B B,SHEN J Z,CAO X Y,et al.Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum[J].Fems Microbiol Letters,2010,308(2):144-149.
[60] LUCIER T S,HEITZMAN K,LIU S K,et al.Transition mutations in the 23SrRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae[J].Antimicrob Agent Chemotherapy,1995,39(12):2770-2773.
[61]吴惠明.耐大环内酯类药物鸡毒支原体的诱导和耐药基因的突变分析[D].北京:中国农业大学,2004.
[62] WU C M,WU H,NING Y,et al.Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domainⅤof 23S rRNA[J].Fems Microbiol Letters,2005,247(2):199-205.
[63]刘玉庆,李璐璐,骆延波,等.EUCAST欧盟药敏试验标准[J].中国标准导报,2016(5):14.
[64]MATTOES H,MNIGHTINGALE C H.Pharmacokinetics/pharmacodynamics of macrolides[J].Birkhuser Basel,2002(1):25-36.
[65] BOSNAR M,KELNERI C'Z,MUNI C'V,et al.Cellular uptake and efflux of azithromycin,erythromycin,clarithromycin,telithromycin,and cethromycin[J].Antimicrob Agent Chemotherapy,2005,49(6):2372-2377.
[66] OLIVERA A,MIZUGISHI K,TIKHONOVA A,et al.The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis[J].Immunity,2007,26(3):287-297.
[67] RAUF M,CHAUDHARY Z I,YOUNUS M,et al.Polypeptide mapping and western blot analysis of Mycoplasma gallisepticum field isolates[J].J Anim Plant Sci,2014,24(1):154-158.
[68] NIGHTINGALE C H.Pharmacokinetics and pharmacodynamics of newer macrolides[J].Pediat Infect Dis J,1997,16(4):438-443.
[69] JAIN RDANZIGER L H.The macrolide antibiotics:a pharmacokinetic and pharmacodynamic overview[J].Curr Pharmaceut Design,2004,25(10):3045-3053.
[70]曾子建,李逐波,古淑英,等.酒石酸泰乐菌素在鸡猪山羊体内的药动学规律及肌肉药残量研究[J].教师教育学报,2000(2):1-5.
[71]李英伦,谢君.复方泰乐菌素注射液的药代动力学研究[J].四川农业大学学报,1998,16(2):256-259.
[72] KOWALSKI C,ROLIN'SKI Z,ZAN'R,et al.Pharmacokinetics of tylosin in broiler chickens[J].Polish J Vet Sci,2002,5(3):127-130.
[73] BRENNAN J,MOORE G,POE S E,et al.Efficacy of infeed tylosin phosphate for the treatment of necrotic enteritis in broiler chickens[J].Poult Sci,2001,80(10):1451.
[74]李建成.替米考星饮水剂的稳定性及其在肉鸡体内的药代动力学研究[D].北京:中国农业大学,2003.
[75]杨娜.LC-MS/MS同时检测鸡体内3种MALs残留及药动学研究[D].安徽合肥:安徽农业大学,2013.
[76] NICKLIN P L,CRAIG S J,PHILLIPS J A.Pharmacokinetic properties of phosphorothioates in animals—absorption,distribution,metabolism and elimination[M].New York:Springer Berlin Heidelberg,1998:141-168.
[77]赵艳红,沈向荣,刘彩,等.磷酸替米考星在肉鸡体内的药代动力学研究[J].江苏农业科学,2013,41(7):207-210.
[78]郭傲民,张军,柴桂珍,等.鸡口服复方替米考星缓释微球的血浆药动学研究[J].黑龙江畜牧兽医,2014(21):46-50.
[79]王建兵.替米考星溶液和磷酸替米考星可溶性粉在肉鸡体内的药动学比较研究[D].江苏扬州:扬州大学,2015.
[80]韩孝欣,王建兵,刘芳,等.两种替米考星可溶性粉在鸡体中的药动学比较研究[J].中国家禽,2015,37(17):27-30.
[81] KELE爦O,BAKIREL T,爦ENER S,et al.Pharmacokinetics and tissue levels of tilmicosin in fowls[J].Turkish J Vet Anim Sci,2014,25(4):629-634.
[82] ABU-BASHA E A,AL-SHUNNAQ A F,GEHRING R.Comparative pharmacokinetics and bioavailability of two tylosin formulations in chickens after oral administration[J].J Hellenic Vet MedSoc,2012,63(2):159-166.
[83] MIYAZAKI M,TOGAMI K,CHONO S,et al.Pharmacokinetic and pharmacodynamic assessment of AUC/MIC of intrapulmonary administered macrolide antimicrobial agents for optimizing the treatment of respiratory infections[C]//Asian pacific regional international society for the study of xenobiotics meeting,1988:1-145.
[84] LIU P,LLER M,DERENDORF H.Rational dosing of antibiotics:the use of plasma concentrations versus tissue concentrations[J].Int J Antimicrob Agent,2002,19(4):285-290.
[85] ANDES D,ANON J,JACOBS M R,et al.Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections[J].Clin Lab Med,2004,24(2):477-502.
[86] MCKELLAR Q A,SANCHEZ BRUNI S F,JONES D G.Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine[J].J Vet Pharmacol Therapeut,2004,27(6):503-514.
[87]余鹏灵,陈良柱,潘志坤,等.恩诺沙星纳米混悬注射剂的制备及在猪体内药动学研究[J].中国兽医学报,2017,37(8):1534-1539..
[88]高延玲,陈杖榴,王付民,等.抗微生物药物PK-PD研究在优化兽药给药方案中的应用[J].中国兽药杂志,2005,39(8):27-31.
[89] MOUTON J W.Breakpoints:current practice and future perspectives[J].Int J Antimicrob Agent,2002,19(4):323-331.
[90] SCH N T,JUR EN P,GISKE C G,et al.Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis[J].J Antimicrob Chemotherapy,2009,64(4):786.
[91] COOPER A C,FULLER J R,FULLER M K,et al.In vitro activity of danofloxacin,tylosin and oxytetracycline against mycoplasmas of veterinary importance[J].Res Vet Sci,1993,54(3):329-334.
[92]宁宜宝.氨苄青霉素-硫氰酸红霉素可溶性粉对鸡毒支原体病的治疗试验[J].中国兽药杂志,2003(5):45-47.
[93] GAUTIER-BOUCHARDON A V,REINHARDT A K,KOBISCH M,et al.In vitro development of resistance to enrofloxacin,erythromycin,tylosin,tiamulin and oxytetracycline in Mycoplasma gallisepticum,Mycoplasma iowae and Mycoplasma synoviae[J].Vet Microbiol,2002,88(1):47-58.
[94]宁宜宝,高和义.泰乐菌素对试管中鸡毒支原体的抑菌试验和对鸡体内鸡毒支原体病的治疗试验[J].河南畜牧兽医,2000(7):6-7,52.
[95]王志强,卜仕金,郑月华,等.替米考星(Tilmicosin)对鸡败血霉形体感染的药效学[J].中国兽医学报,2004,24(4):386-388.
[96]王丽平,江善祥,史晓丽,等.替米考星的体外抑菌试验和其磷酸盐预混剂对鸡慢性呼吸道病的疗效试验[J].中国兽医科技,2003(9):55-59.
[97]谷增昌,段定然.鸡霉形体病的危害及防制[J].云南畜牧兽医,2013(4):17-18.
[98]储宝玲,李国智.鸡慢性呼吸道疾病的防治策略[J].当代畜禽养殖业,2016(1):59.
[99]李红萍,邹勇,帅华平,等.鸡霉形体病的诊治[J].福建畜牧兽医,2009(1):35-36.
[100]田碧霞,徐雄真,邓华成,等.鸡毒支原体感染的诊断及防制[J].贵州畜牧兽医,2016(5):44-46.
[101]史秀玲.鸡败血霉形体病流行和诊治方案[J].中国畜禽种业,2017(2):156.
[102]王丽,左广双.鸡毒支原体感染的防治[J].兽医导刊,2015(7):57-58.
[103]李先明.鸡呼吸道疾病的诊断与防制[J].畜牧兽医科技信息,2016(10):118-120.
[104]周云凤.泰乐菌素新制剂对猪鸡支原体临床治疗与预防效果观察[D].江苏南京:南京农业大学,2007.
[105] FORRESTER C A,BRADBURY J M,DARE C M,et al.Mycoplasma gallisepticum in pheasants and the efficacy of tylvalosin to treat the disease[J].Avian Pathol J,2011,40(6):581.
[106]胡功政,吴华,李敏,等.罗红霉素对鸡霉形体病的药效观察[J].中国兽医杂志,2001(5):16-17.
[107]宋奎富,李达焱.罗红霉素对鸡毒支原体感染的治疗试验[J].当代畜禽养殖业,2004(2):36-38.
[108] EL-SAMIE L K A.Evaluation of tilmicosin in treatment of Mycoplasma gallisepticum infected chickens[J].Assiut Vet Med J,2014,60(142):139-143.
[109]韩孝欣.磷酸替米考星可溶性粉对鸡支原体感染的疗效及在鸡体内残留消除研究[D].江苏扬州:扬州大学,2016.
[110]范建华,何友义,韦玉勇,等.磷酸替米考星可溶性粉对人工感染鸡毒支原体的疗效试验[J].中国兽药杂志,2014(6):58-61.
[111]宗昕如,张晓辉,辛凌翔,等.磷酸替米考星可溶性粉对人工感染鸡支原体的治疗试验[J].畜牧与兽医,2013(8):88-92.
[2]LEVISOHN SKLEVEN S H.Avian mycoplasmosis(Mycoplasma gallisepticum)[J].Rev Scientif Et Tech,2000,19(2):425-442.
[3]PENNYCOTT T W.Causes of mortality and culling in adult pheasants[J].Vet Rec,2000,146(10):273-278.
[4]BENCINA D,MRZEL I,ROJS O Z,et al.Characterisation of Mycoplasma gallisepticumstrains involved in respiratory disease in pheasants and peafowl[J].Vet Rec,2003,152(8):230.
[5]XIAO X,SUN J,CHEN Y,et al.Ex vivo pharmacokinetic and pharmacodynamic analysis of valnemulin against Mycoplasma gallisepticum S6in Mycoplasma gallisepticumand Escherichia coli co-infected chickens[J].Vet J,2015,204(1):54-59.
[6]RAUTIAIN E N,EWALLGREN P.Aspects of the transmission of protection against Mycoplasma hyopneumoniae from sow to offspring[J].J Vet Med,2001,48(1):55-65.
[7]SWAYNE D E,GLISSON J R,MCDOUGALD L R,et al.Diseases of poultry[M].Ames,IA:Iowa State University Press,2013.
[8]BENOINA D,TADINA T,DORRER D.Natural infection of geese with Mycoplasma gallisepticum and Mycoplasma synoviae and egg transmission of the mycoplasmas[J].Avian Pathol,1988,17(2):441-449.
[9]MAROIS C,DUFOUR-GESBERT F,KEMPF I.Polymerase chain reaction for detection of Mycoplasma gallisepticumin environmental samples[J].Avian Pathol,2002,31(2):163.
[10] SASIPREEYAJAN J,HALVORSON D A,NEWMAN J A.Bacterin to control the vertical transmission of Mycoplasma gallisepticum in chickens[J].Avian Dis,1985,29(4):1256.
[11] REIMSCHUESSEL R,MILLER R A,GIESEKER C M.Antimicrobial drug use in aquaculture[M]//Antimicrobial therapy in veterinary medicine.Fifth edition.John Wiley&Sons,Inc,2013:569-587.
[12] NAN Z,YE X,WU Y,et al.Determination of the mutant selection window and evaluation of the killing of Mycoplasma gallisepticum by danofloxacin,doxycycline,tilmicosin,tylvalosin and valnemulin[J].PLoS One,2017,12(1):e0169134.
[13] SULEJMAN A,DANIELE A,ANDREA B,et al.Macrolides[J].Kirk-Othmer Encyclopedia Chem Technol,2008,53(5):374-377.
[14]林伯全,廖惠珍,杜海江,等.免疫鸡毒支原体F弱毒株对SPF鸡Bu-1a+B、TCRγδ+CD3+T细胞及血清IgM、IgG、IgA的影响[J].中国兽医学报,2015,35(4):549-552.
[15] FEIZI A,BABAKHANI S,NIKPIRAN H.Seroprevalence of Mycoplasma gallisepticuminfection in Iranian north-west broiler breeder farms[J].An Biol Res,2013,4(4):109-111.
[16] GERCHMAN I.Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry[J].Vet Res,2011,42(1):90.
[17] ZANELLA A,MARTINO P A,PRATELLI A,et al.Development of antibiotic resistance in Mycoplasma gallisepticum in vitro[J].Avian Pathol,1998,27(6):591-596.
[18] GHARAIBEH SAL-RASHDAN M.Change in antimicrobial susceptibility of Mycoplasma gallisepticumfield isolates[J].Vet Microbiol,2011,150(3/4):379.
[19] SAMUEL S O,ABODERIN A O,SALAMI T A T,et al.Campylobacter antimicrobial drug resistance among humans in Ilorin,Nigeria[J].Nigerian Med J,2009(1):56.
[20] TURNIDGE JPATERSON D L.Setting and revising antibacterial susceptibility breakpoints[J].Clin Microbiol Rev,2007,20(3):391.
[21]赵源昌.细菌对抗菌药物的敏感性试验[J].农家之友(理论版),2008(11):53-56.
[22] BROWN DMACGOWAN A.Harmonization of antimicrobial susceptibility testing breakpoints in Europe:implications for reporting intermediate susceptibility[J].J Antimicrob Chemother,2010,65(2):183-185.
[23] BYWATER R,SILLEY P,SIMJEE S.Antimicrobial breakpoints—Definitions and conflicting requirements[J].Vet Microbiol,2006,118(1/2):158.
[24] STASS HDALHOFF A.The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints[J].Infection,2005,33(2):29-35.
[25] SOUSSY C J,CLUZEL R,COURVALIN P.Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France[J].Eur J Clin Microbiol Infect Dis,1994,13(3):238-246.
[26] TURNIDGE J,KAHLMETER G,KRONVALL G.Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values[J].Clin Microbiol Infect Off Publicat Eur Soc Clin Microbiol Infect Dis,2006,12(5):418.
[27] BTTNER A,DE J A,SCHMID P,et al.Determination of breakpoints for veterinary medically relevant antibiotics for resistance assessment of veterinary pathogens[J].Berliner Und Münchener Tierrztliche Wochenschrift,2000,113(9):344-347.
[28]童明庆.抗菌药的PK/PD理论及其在新抗菌药的药效研究中应用[J].中国临床药理学杂志,2008,24(5):475-480.
[29] XU C,ZHANG J,ZHAO Z,et al.Antimicrobial susceptibility and PFGE genotyping of Haemophilus parasuis isolates from pigs in South China(2008-2010)[J].J Vet Med Sci,2011,73(8):1061.
[30]潘华芳.猪沙门菌对恩诺沙星耐药判定标准研究[D].湖北武汉:华中农业大学,2012.
[31]张朋.副猪嗜血杆菌对替米考星野生型折点和药效学折点研究[D].湖北武汉:华中农业大学,2015.
[32] JACOBS M R,MITHAL Y,ROBINSBROWNE R M,et al.Antimicrobial susceptibility testing of pneumococci:determination of Kirby-Bauer breakpoints for penicillin G,erythromycin,clindamycin,tetracycline,chloramphenicol,and rifampin[J].Antimicrob Agents Chemotherapy,1979,16(2):190-197.
[33]曾振灵,王燕,王令,等.三种抗菌药体外对鸡败血支原体的敏感性[J].中国预防兽医学报,2002(2):48-50.
[34]李宏胜,张继瑜,周绪正,等.替米考星与泰乐菌素对畜禽常见病原菌抑菌作用比较[J].动物医学进展,2006,27(2):94-96.
[35]刘轶秋,张媛,薛青红,等.恩诺沙星与其他抗菌药对鸡毒支原体的体外联合抑菌试验[J].中国兽药杂志,2013(12):46-50.
[36]王建国.鸡毒支原体大环内酯类耐药性诱导及其核蛋白突变分析[D].北京:中国农业大学,2006.
[37]陈凤梅,牛钟相,程光民,等.替米考星用于鸡毒支原体和大肠杆菌混合感染的临床试验[J].中国家禽,2004(21):17-19.
[38]王志强,卜仕金,郑月华,等.替米考星(tilmicosin)对鸡败血霉形体感染的药效学[J].中国兽医学报,2004,24(4):386-388.
[39]颜友荣,方向红.替米考星对鸡败血支原体的体外抑菌试验[J].畜牧兽医杂志,2007(3):8-10.
[40]钟妮娜,王红宁,廖德惠,等.抗菌药物联合应用对鸡毒支原体的药敏试验[J].中国兽医杂志,1998(8):7-8.
[41]孔意端,林居纯,陈继荣,等.鸡毒支原体不同地区分离株对常用抗菌药物的敏感性试验[J].动物医学进展,2008(6):35-38.
[42]郭伟娜.鸡毒霉形体不同菌株的药敏实验及耐药机制的研究[D].湖北武汉:华中农业大学,2007.
[43]李东.湖北地区鸡毒霉形体的分离鉴定及分子流行病学研究[D].湖北武汉:华中农业大学,2011.
[44]林居纯,曾振灵,吴聪明,等.鸡毒支原体的耐药性调查[J].中国兽医杂志,2008(8):40-41.
[45]隋兆峰,张侃吉,徐建义,等.山东地区鸡毒支原体分离鉴定及耐药性监测[J].中国家禽,2016(14):51-54.
[46]徐建义.山东地区肉鸡鸡败血支原体感染流行病学调查及综合防治措施的非军事化[D].江苏南京:南京农业大学,2005.
[47] JORDAN F T W,FORRESTER C A,RIPLEY P H,et al.In vitro and in vivo comparisons of valnemulin,tiamulin,tylosin,enrofloxacin,and lincomycin/spectinomycin against Mycoplasma gallisepticum[J].Avian Dis,1998,42(4):738-745.
[48] AMMAR A M,ABD ELAZIZ N K,GHARIB A A,et al.Mutations of domainⅤin 23Sribosomal RNA of macrolide-resistant Mycoplasma gallisepticum isolates in Egypt[J].J Infect Deve Countries,2016,10(8):807.
[49] JOHN T L P D.Setting and revising antibacterial susceptibility break points[J].Clin Microbiol Rev,2007,20(3):1245.
[50]王强,霍伟,任元刚,等.鸡霉形体的分离与药敏试验[J].山东畜牧兽医,2016(9):11-12.
[51] KATZ LASHLEY G W.Translation and protein synthesis:macrolides[J].Chem Rev,2005,105(2):499-528.
[52] JENNI SBAN N.The chemistry of protein synthesis and voyage through the ribosomal tunnel[J].Curr Opin Struct Biol,2003,13(2):212-219.
[53] KANOH SRUBIN B K.Mechanisms of action and clinical application of macrolides as immunomodulatory medications[J].Clin Microbiol Rev,2010,23(3):590.
[54]李玉保,王守荣,刘玉庆,等.肉鸡气管阻塞呼吸系统细菌多样性分析[J].中国兽医学报,2016,36(7):1123-1130.
[55]VESTER BDOUTHWAITE S.Macrolide resistance conferred by base substitutions in 23SrRNA[J].Antimicrob Agent Chemotherapy,2001,45(1):1.
[56] DUMKE R,TH RMER A,JACOBS E.Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden,Germany[J].Diagn Microbiol Infect Dis,2016,86(2):221.
[57] ROBERTS M C,SUTCLIFFE J,COURVALIN P,et al.Nomenclature for macrolide and macrolide-lincosamidestreptogramin B resistance determinants[J].Antimicrob Agent Chemotherapy,1999,43(12):2823.
[58] FELMINGHAM D,ROBBINS M J,SANGHRAJKA M,et al.The in vitro activity of some 14-,15-and 16-membered macrolides against Staphylococcus spp.,Legionella spp.,Mycoplasma spp.and Ureaplasma urealyticum[J].Drug Under Exp Clin Res,1991,17(2):91-99.
[59] LI B B,SHEN J Z,CAO X Y,et al.Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum[J].Fems Microbiol Letters,2010,308(2):144-149.
[60] LUCIER T S,HEITZMAN K,LIU S K,et al.Transition mutations in the 23SrRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae[J].Antimicrob Agent Chemotherapy,1995,39(12):2770-2773.
[61]吴惠明.耐大环内酯类药物鸡毒支原体的诱导和耐药基因的突变分析[D].北京:中国农业大学,2004.
[62] WU C M,WU H,NING Y,et al.Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domainⅤof 23S rRNA[J].Fems Microbiol Letters,2005,247(2):199-205.
[63]刘玉庆,李璐璐,骆延波,等.EUCAST欧盟药敏试验标准[J].中国标准导报,2016(5):14.
[64]MATTOES H,MNIGHTINGALE C H.Pharmacokinetics/pharmacodynamics of macrolides[J].Birkhuser Basel,2002(1):25-36.
[65] BOSNAR M,KELNERI C'Z,MUNI C'V,et al.Cellular uptake and efflux of azithromycin,erythromycin,clarithromycin,telithromycin,and cethromycin[J].Antimicrob Agent Chemotherapy,2005,49(6):2372-2377.
[66] OLIVERA A,MIZUGISHI K,TIKHONOVA A,et al.The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis[J].Immunity,2007,26(3):287-297.
[67] RAUF M,CHAUDHARY Z I,YOUNUS M,et al.Polypeptide mapping and western blot analysis of Mycoplasma gallisepticum field isolates[J].J Anim Plant Sci,2014,24(1):154-158.
[68] NIGHTINGALE C H.Pharmacokinetics and pharmacodynamics of newer macrolides[J].Pediat Infect Dis J,1997,16(4):438-443.
[69] JAIN RDANZIGER L H.The macrolide antibiotics:a pharmacokinetic and pharmacodynamic overview[J].Curr Pharmaceut Design,2004,25(10):3045-3053.
[70]曾子建,李逐波,古淑英,等.酒石酸泰乐菌素在鸡猪山羊体内的药动学规律及肌肉药残量研究[J].教师教育学报,2000(2):1-5.
[71]李英伦,谢君.复方泰乐菌素注射液的药代动力学研究[J].四川农业大学学报,1998,16(2):256-259.
[72] KOWALSKI C,ROLIN'SKI Z,ZAN'R,et al.Pharmacokinetics of tylosin in broiler chickens[J].Polish J Vet Sci,2002,5(3):127-130.
[73] BRENNAN J,MOORE G,POE S E,et al.Efficacy of infeed tylosin phosphate for the treatment of necrotic enteritis in broiler chickens[J].Poult Sci,2001,80(10):1451.
[74]李建成.替米考星饮水剂的稳定性及其在肉鸡体内的药代动力学研究[D].北京:中国农业大学,2003.
[75]杨娜.LC-MS/MS同时检测鸡体内3种MALs残留及药动学研究[D].安徽合肥:安徽农业大学,2013.
[76] NICKLIN P L,CRAIG S J,PHILLIPS J A.Pharmacokinetic properties of phosphorothioates in animals—absorption,distribution,metabolism and elimination[M].New York:Springer Berlin Heidelberg,1998:141-168.
[77]赵艳红,沈向荣,刘彩,等.磷酸替米考星在肉鸡体内的药代动力学研究[J].江苏农业科学,2013,41(7):207-210.
[78]郭傲民,张军,柴桂珍,等.鸡口服复方替米考星缓释微球的血浆药动学研究[J].黑龙江畜牧兽医,2014(21):46-50.
[79]王建兵.替米考星溶液和磷酸替米考星可溶性粉在肉鸡体内的药动学比较研究[D].江苏扬州:扬州大学,2015.
[80]韩孝欣,王建兵,刘芳,等.两种替米考星可溶性粉在鸡体中的药动学比较研究[J].中国家禽,2015,37(17):27-30.
[81] KELE爦O,BAKIREL T,爦ENER S,et al.Pharmacokinetics and tissue levels of tilmicosin in fowls[J].Turkish J Vet Anim Sci,2014,25(4):629-634.
[82] ABU-BASHA E A,AL-SHUNNAQ A F,GEHRING R.Comparative pharmacokinetics and bioavailability of two tylosin formulations in chickens after oral administration[J].J Hellenic Vet MedSoc,2012,63(2):159-166.
[83] MIYAZAKI M,TOGAMI K,CHONO S,et al.Pharmacokinetic and pharmacodynamic assessment of AUC/MIC of intrapulmonary administered macrolide antimicrobial agents for optimizing the treatment of respiratory infections[C]//Asian pacific regional international society for the study of xenobiotics meeting,1988:1-145.
[84] LIU P,LLER M,DERENDORF H.Rational dosing of antibiotics:the use of plasma concentrations versus tissue concentrations[J].Int J Antimicrob Agent,2002,19(4):285-290.
[85] ANDES D,ANON J,JACOBS M R,et al.Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections[J].Clin Lab Med,2004,24(2):477-502.
[86] MCKELLAR Q A,SANCHEZ BRUNI S F,JONES D G.Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine[J].J Vet Pharmacol Therapeut,2004,27(6):503-514.
[87]余鹏灵,陈良柱,潘志坤,等.恩诺沙星纳米混悬注射剂的制备及在猪体内药动学研究[J].中国兽医学报,2017,37(8):1534-1539..
[88]高延玲,陈杖榴,王付民,等.抗微生物药物PK-PD研究在优化兽药给药方案中的应用[J].中国兽药杂志,2005,39(8):27-31.
[89] MOUTON J W.Breakpoints:current practice and future perspectives[J].Int J Antimicrob Agent,2002,19(4):323-331.
[90] SCH N T,JUR EN P,GISKE C G,et al.Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis[J].J Antimicrob Chemotherapy,2009,64(4):786.
[91] COOPER A C,FULLER J R,FULLER M K,et al.In vitro activity of danofloxacin,tylosin and oxytetracycline against mycoplasmas of veterinary importance[J].Res Vet Sci,1993,54(3):329-334.
[92]宁宜宝.氨苄青霉素-硫氰酸红霉素可溶性粉对鸡毒支原体病的治疗试验[J].中国兽药杂志,2003(5):45-47.
[93] GAUTIER-BOUCHARDON A V,REINHARDT A K,KOBISCH M,et al.In vitro development of resistance to enrofloxacin,erythromycin,tylosin,tiamulin and oxytetracycline in Mycoplasma gallisepticum,Mycoplasma iowae and Mycoplasma synoviae[J].Vet Microbiol,2002,88(1):47-58.
[94]宁宜宝,高和义.泰乐菌素对试管中鸡毒支原体的抑菌试验和对鸡体内鸡毒支原体病的治疗试验[J].河南畜牧兽医,2000(7):6-7,52.
[95]王志强,卜仕金,郑月华,等.替米考星(Tilmicosin)对鸡败血霉形体感染的药效学[J].中国兽医学报,2004,24(4):386-388.
[96]王丽平,江善祥,史晓丽,等.替米考星的体外抑菌试验和其磷酸盐预混剂对鸡慢性呼吸道病的疗效试验[J].中国兽医科技,2003(9):55-59.
[97]谷增昌,段定然.鸡霉形体病的危害及防制[J].云南畜牧兽医,2013(4):17-18.
[98]储宝玲,李国智.鸡慢性呼吸道疾病的防治策略[J].当代畜禽养殖业,2016(1):59.
[99]李红萍,邹勇,帅华平,等.鸡霉形体病的诊治[J].福建畜牧兽医,2009(1):35-36.
[100]田碧霞,徐雄真,邓华成,等.鸡毒支原体感染的诊断及防制[J].贵州畜牧兽医,2016(5):44-46.
[101]史秀玲.鸡败血霉形体病流行和诊治方案[J].中国畜禽种业,2017(2):156.
[102]王丽,左广双.鸡毒支原体感染的防治[J].兽医导刊,2015(7):57-58.
[103]李先明.鸡呼吸道疾病的诊断与防制[J].畜牧兽医科技信息,2016(10):118-120.
[104]周云凤.泰乐菌素新制剂对猪鸡支原体临床治疗与预防效果观察[D].江苏南京:南京农业大学,2007.
[105] FORRESTER C A,BRADBURY J M,DARE C M,et al.Mycoplasma gallisepticum in pheasants and the efficacy of tylvalosin to treat the disease[J].Avian Pathol J,2011,40(6):581.
[106]胡功政,吴华,李敏,等.罗红霉素对鸡霉形体病的药效观察[J].中国兽医杂志,2001(5):16-17.
[107]宋奎富,李达焱.罗红霉素对鸡毒支原体感染的治疗试验[J].当代畜禽养殖业,2004(2):36-38.
[108] EL-SAMIE L K A.Evaluation of tilmicosin in treatment of Mycoplasma gallisepticum infected chickens[J].Assiut Vet Med J,2014,60(142):139-143.
[109]韩孝欣.磷酸替米考星可溶性粉对鸡支原体感染的疗效及在鸡体内残留消除研究[D].江苏扬州:扬州大学,2016.
[110]范建华,何友义,韦玉勇,等.磷酸替米考星可溶性粉对人工感染鸡毒支原体的疗效试验[J].中国兽药杂志,2014(6):58-61.
[111]宗昕如,张晓辉,辛凌翔,等.磷酸替米考星可溶性粉对人工感染鸡支原体的治疗试验[J].畜牧与兽医,2013(8):88-92.